Literature DB >> 7960246

Intrinsic MDR-1 gene and P-glycoprotein expression in human melanoma cell lines.

W Berger1, L Elbling, M Minai-Pour, M Vetterlein, R Pirker, E M Kokoschka, M Micksche.   

Abstract

Metastatic malignant melanoma is considered a chemotherapy-refractory malignancy. A few previous studies have delivered contradictory results regarding the presence and functionality of P-glycoprotein (P-gp), a transmembranous protein associated with the classical multidrug resistance (cMDR), in malignant melanoma. Therefore we have investigated this issue on 33 cell lines established from primary and metastatic lesions of human malignant melanoma, comparing different cMDR detection methods. Immunocytochemically 33% of the cell lines stained positive for P-gp. The data correlated with those of a P-gp-radioimmunometric (antibody-binding) assay. When RT-PCR was used for MDR-1 mRNA determination, 76% of the melanoma cell lines scored positive. Slot-blot analysis was seen to be less sensitive than RT-PCR. Results from the functional P-gp assays, using daunomycin (DM) as MDR-substrate, showed no influence of P-gp expression on drug accumulation and cytotoxicity. However, the cMDR-modifier verapamil (VP) significantly increased both parameters in those melanoma cells with the highest P-gp levels. We conclude that cMDR is apparently not the decisive but probably a complementary protective mechanism against toxic agents in malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7960246     DOI: 10.1002/ijc.2910590522

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Congenital expression of mdr-1 gene in tissues of carcinoma and its relation with pathomorphology and prognosis.

Authors:  Li-Jian Zhang; Ke-Neng Chen; Guang-Wei Xu; Hai-Ping Xing; Xiao-Tian Shi
Journal:  World J Gastroenterol       Date:  1999-02       Impact factor: 5.742

2.  Differential expression patterns of capping protein, protein phosphatase 1, and casein kinase 1 may serve as diagnostic markers for malignant melanoma.

Authors:  Daxin Sun; Mian Zhou; Claudia M Kowolik; Vijay Trisal; Qin Huang; Kemp H Kernstine; Fangru Lian; Binghui Shen
Journal:  Melanoma Res       Date:  2011-08       Impact factor: 3.599

3.  Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.

Authors:  Tamás Garay; Eszter Molnár; Éva Juhász; Viktória László; Tamás Barbai; Judit Dobos; Karin Schelch; Christine Pirker; Michael Grusch; Walter Berger; József Tímár; Balázs Hegedűs
Journal:  Pathol Oncol Res       Date:  2015-03-09       Impact factor: 3.201

4.  Anticancer activity of methyl-substituted oxaliplatin analogs.

Authors:  Ute Jungwirth; Dimitris N Xanthos; Johannes Gojo; Anna K Bytzek; Wilfried Körner; Petra Heffeter; Sergey A Abramkin; Michael A Jakupec; Christian G Hartinger; Ursula Windberger; Markus Galanski; Bernhard K Keppler; Walter Berger
Journal:  Mol Pharmacol       Date:  2012-02-13       Impact factor: 4.436

5.  Melanoma chemotherapy leads to the selection of ABCB5-expressing cells.

Authors:  Marine Chartrain; Joëlle Riond; Aline Stennevin; Isabelle Vandenberghe; Bruno Gomes; Laurence Lamant; Nicolas Meyer; Jean Edouard Gairin; Nicolas Guilbaud; Jean Philippe Annereau
Journal:  PLoS One       Date:  2012-05-24       Impact factor: 3.240

6.  CCR4 is a determinant of melanoma brain metastasis.

Authors:  Anat Klein; Orit Sagi-Assif; Tsipi Meshel; Alona Telerman; Sivan Izraely; Shlomit Ben-Menachem; Jagadeesh Bayry; Diego M Marzese; Shuichi Ohe; Dave S B Hoon; Neta Erez; Isaac P Witz
Journal:  Oncotarget       Date:  2017-05-09

7.  Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24).

Authors:  P Heffeter; M A Jakupec; W Körner; P Chiba; C Pirker; R Dornetshuber; L Elbling; H Sutterlüty; M Micksche; B K Keppler; W Berger
Journal:  Biochem Pharmacol       Date:  2007-03-12       Impact factor: 5.858

8.  Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma.

Authors:  S Spiegl-Kreinecker; C Pirker; C Marosi; J Buchroithner; J Pichler; R Silye; J Fischer; M Micksche; W Berger
Journal:  Br J Cancer       Date:  2007-03-06       Impact factor: 7.640

9.  Anticancer properties of peptide fragments of hair proteins.

Authors:  Sergiusz Markowicz; Joanna Matalinska; Katarzyna Kurzepa; Marta Bochynska; Marzena Biernacka; Anna Samluk; Dorota Dudek; Henryk Skurzak; Masaaki Yoshikawa; Andrzej W Lipkowski
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

10.  Cystatin C takes part in melanoma-microglia cross-talk: possible implications for brain metastasis.

Authors:  Adi Moshe; Sivan Izraely; Orit Sagi-Assif; Roshini Prakash; Alona Telerman; Tsipi Meshel; Thomas Carmichael; Isaac P Witz
Journal:  Clin Exp Metastasis       Date:  2018-05-02       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.